Literature DB >> 23121858

Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder.

D Amital1, L Fostick, A Silberman, R Calati, C Spindelegger, A Serretti, A Juven-Wetzler, D Souery, J Mendlewicz, S Montgomery, S Kasper, J Zohar.   

Abstract

Co-morbid physical illness has been suggested to play an important role among the factors contributing to treatment resistance in patients with major depressive disorder. In the current study we compared the rate of physical co-morbidity, defined by ICD-10, among a large multicenter sample of 702 patients with major depressive disorder. A total of 356 of the participants were defined as treatment resistant depression (TRD) patients-having failed two or more adequate antidepressant trials. No significant difference was found between TRD and non-TRD participants in the prevalence of any ICD-10 category. This finding suggests that although physical conditions such as diabetes, thyroid dysfunction, hypertension, ischemic heart disease, and peptic diseases are often accompanied by co-morbid MDD, they do not necessarily have an impact on the course of MDD or the likelihood to respond to treatment. Marginally higher rates of co-morbid breast cancer, migraine and glaucoma were found among TRD participants. Possible explanations for these findings and their possible relation to TRD are discussed.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Depression; Physical co-morbidity; Treatment resistance; Treatment response

Mesh:

Substances:

Year:  2012        PMID: 23121858     DOI: 10.1016/j.euroneuro.2012.09.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

1.  The lack of association between components of metabolic syndrome and treatment resistance in depression.

Authors:  Marina Sagud; Alma Mihaljevic-Peles; Suzana Uzun; Bjanka Vuksan Cusa; Oliver Kozumplik; Suzan Kudlek-Mikulic; Maja Mustapic; Ivan Barisic; Dorotea Muck-Seler; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2013-04-12       Impact factor: 4.530

Review 2.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

3.  Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis.

Authors:  Péter Döme; Péter Kunovszki; Péter Takács; László Fehér; Tamás Balázs; Károly Dede; Siobhán Mulhern-Haughey; Sébastien Barbreau; Zoltán Rihmer
Journal:  PLoS One       Date:  2021-01-20       Impact factor: 3.240

Review 4.  Clinical research challenges posed by difficult-to-treat depression.

Authors:  A John Rush; Harold A Sackeim; Charles R Conway; Mark T Bunker; Steven D Hollon; Koen Demyttenaere; Allan H Young; Scott T Aaronson; Maxine Dibué; Michael E Thase; R Hamish McAllister-Williams
Journal:  Psychol Med       Date:  2022-01-07       Impact factor: 7.723

5.  Healthcare resource utilization in patients with treatment-resistant depression-A Danish national registry study.

Authors:  Kristoffer Jarlov Jensen; Frederikke Hørdam Gronemann; Mikkel Zöllner Ankarfeldt; Espen Jimenez-Solem; Sarah Alulis; Jesper Riise; Nikolaj Bødker; Merete Osler; Janne Petersen
Journal:  PLoS One       Date:  2022-09-27       Impact factor: 3.752

6.  Aripiprazole in the treatment of refractory mood disorders: a case series.

Authors:  Ather Muneer
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-08-12       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.